Tradition May Lead To AIDS Vaccine

February 16, 2003 - 0:0
BOSTON -- For the first time in years, AIDS scientists are finding promising paths to follow on the traditional route to a vaccine.

Virtually all vaccines work by stimulating the immune system to make antibodies -- small proteins that target invading microbes and toxins in a highly specific way, coat them and tag them for destruction. Vaccines against diseases such as influenza and tetanus stimulate antibody production with such efficiency that the pathogen never has a chance to take hold, or if it does, only momentarily.

In the case of AIDS, it has been very hard to identify what type of antibody, if any, actually protects a person against infection, not to mention how to get the immune system to make such a substance. For that reason, much of AIDS research in recent years has focused on vaccines that do not prevent infection, but instead prime the body to fight a permanent war of suppression through "cell-mediated" immunity, ***** Washington Post **** reported.

At the 10th Conference on Retroviruses and Opportunistic Infections, which drew about 4,000 AIDS researchers here this week, it is clear that vaccine scientists have not given up on finding a vaccine that stimulates so-called "neutralizing" antibodies, just as traditional vaccines do. And, at least in laboratory studies, they're finally getting traction. "There's a shifting of the pendulum," said Carol D. Weiss, a vaccine researcher at the Food and Drug Administration. "We've had the most experience with antibody, and we know that antibody can give 'sterilizing' immunity in many diseases."

Traditionally, vaccine-makers used some version of the disease-causing microbe itself as the vaccine.

It was either killed or weakened to the point where it could not cause disease, and then introduced into the body. (In some vaccines, such as the one against hepatitis B, only a piece of the offending virus is used.) At that point, the immune system takes over and decides what parts of the microbe's structure are the best targets.

Specific immune-system cells then churn out trillions of antibody molecules custom-fitted to those targets.

In the case of human immunodeficiency virus (HIV), however, this strategy has not worked. Live, weakened virus is deemed too dangerous to use as a vaccine. Killed virus has been tried as a way of boosting the immune system of already-infected people, but it did little good. Some AIDS vaccines using harmless pieces of the virus (such as parts of its outer shell) are being tested in large trials, and their effectiveness is unknown.

In the new research presented here, vaccine scientists are betting they can give the immune system better instructions on what kind of antibody to make than it has been able to come up with on its own.

"We're not playing by the same rules as natural infection," said Dennis R. Burton, a vaccine researcher at the Scripps Research Institute in La Jolla, Calif.

HIV is a highly variable microbe. One the many problems is that for a vaccine to be useful, it must protect against many different strains of virus. In the research described here this week, scientists are targeting minuscule regions of HIV's surface structure that never vary because they play essential roles in the virus's act of docking on a cell under attack.

Identifying those regions is very difficult.

Burton today described how his team found in a "library" of antibodies from HIV-infected people that, in cell cultures, prevented infection by almost all HIV strains. The team then identified exactly where the antibody slipped between virus and cell to block attachment. The scientists are now designing a compound that when injected into human beings -- they hope -- will stimulate antibodies of precisely that shape.

Similarly, Weiss described how she and colleagues at the FDA made small proteins that mimicked a tiny part of HIV called gp41 involved in the step where the virus and cell membranes fuse, allowing the virus to dump its contents inside. When injected into rabbits, those proteins stimulated the production of antibodies that blocked fusion under some -- although not all -- conditions.

While these strategies look promising, Weiss believes a successful vaccine will ultimately contain substances that both stimulate antibodies and cell-mediated immunity.

"Personally, I think the more, the better," she said.